248 related articles for article (PubMed ID: 11439339)
1. TRAIL (APO-2L) induces apoptosis in human prostate cancer cells that is inhibitable by Bcl-2.
Munshi A; Pappas G; Honda T; McDonnell TJ; Younes A; Li Y; Meyn RE
Oncogene; 2001 Jun; 20(29):3757-65. PubMed ID: 11439339
[TBL] [Abstract][Full Text] [Related]
2. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II.
Ravi R; Bedi A
Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014
[TBL] [Abstract][Full Text] [Related]
3. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
[TBL] [Abstract][Full Text] [Related]
4. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
Ozören N; El-Deiry WS
Neoplasia; 2002; 4(6):551-7. PubMed ID: 12407450
[TBL] [Abstract][Full Text] [Related]
5. Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL.
Voelkel-Johnson C; King DL; Norris JS
Cancer Gene Ther; 2002 Feb; 9(2):164-72. PubMed ID: 11857034
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels.
Nimmanapalli R; Perkins CL; Orlando M; O'Bryan E; Nguyen D; Bhalla KN
Cancer Res; 2001 Jan; 61(2):759-63. PubMed ID: 11212279
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapeutic agents enhance TRAIL-induced apoptosis in prostate cancer cells.
Munshi A; McDonnell TJ; Meyn RE
Cancer Chemother Pharmacol; 2002 Jul; 50(1):46-52. PubMed ID: 12111111
[TBL] [Abstract][Full Text] [Related]
8. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
Kang J; Bu J; Hao Y; Chen F
Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
[TBL] [Abstract][Full Text] [Related]
9. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.
Zhang XD; Borrow JM; Zhang XY; Nguyen T; Hersey P
Oncogene; 2003 May; 22(19):2869-81. PubMed ID: 12771938
[TBL] [Abstract][Full Text] [Related]
10. Persistent c-FLIP(L) expression is necessary and sufficient to maintain resistance to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in prostate cancer.
Zhang X; Jin TG; Yang H; DeWolf WC; Khosravi-Far R; Olumi AF
Cancer Res; 2004 Oct; 64(19):7086-91. PubMed ID: 15466204
[TBL] [Abstract][Full Text] [Related]
11. Bcl-2 oncoprotein protects the human prostatic carcinoma cell line PC3 from TRAIL-mediated apoptosis.
Rokhlin OW; Guseva N; Tagiyev A; Knudson CM; Cohen MB
Oncogene; 2001 May; 20(22):2836-43. PubMed ID: 11420695
[TBL] [Abstract][Full Text] [Related]
12. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells.
Lane D; Cartier A; L'Espérance S; Côté M; Rancourt C; Piché A
Gynecol Oncol; 2004 Jun; 93(3):594-604. PubMed ID: 15196850
[TBL] [Abstract][Full Text] [Related]
13. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
Ng CP; Zisman A; Bonavida B
Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapeutic agents sensitize sarcoma cell lines to tumor necrosis factor-related apoptosis-inducing ligand-induced caspase-8 activation, apoptosis and loss of mitochondrial membrane potential.
Hotta T; Suzuki H; Nagai S; Yamamoto K; Imakiire A; Takada E; Itoh M; Mizuguchi J
J Orthop Res; 2003 Sep; 21(5):949-57. PubMed ID: 12919886
[TBL] [Abstract][Full Text] [Related]
15. Reactive oxygen species regulate caspase activation in tumor necrosis factor-related apoptosis-inducing ligand-resistant human colon carcinoma cell lines.
Izeradjene K; Douglas L; Tillman DM; Delaney AB; Houghton JA
Cancer Res; 2005 Aug; 65(16):7436-45. PubMed ID: 16103097
[TBL] [Abstract][Full Text] [Related]
16. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M
Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347
[TBL] [Abstract][Full Text] [Related]
17. Ionizing radiation enhances the therapeutic potential of TRAIL in prostate cancer in vitro and in vivo: Intracellular mechanisms.
Shankar S; Singh TR; Srivastava RK
Prostate; 2004 Sep; 61(1):35-49. PubMed ID: 15287092
[TBL] [Abstract][Full Text] [Related]
18. Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand.
Kim EJ; Suliman A; Lam A; Srivastava RK
Int J Oncol; 2001 Jan; 18(1):187-94. PubMed ID: 11115558
[TBL] [Abstract][Full Text] [Related]
19. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells.
Walczak H; Bouchon A; Stahl H; Krammer PH
Cancer Res; 2000 Jun; 60(11):3051-7. PubMed ID: 10850456
[TBL] [Abstract][Full Text] [Related]
20. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells.
Knight MJ; Riffkin CD; Muscat AM; Ashley DM; Hawkins CJ
Oncogene; 2001 Sep; 20(41):5789-98. PubMed ID: 11593384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
